Halozyme Therapeutics (HALO) Interest Expenses (2011 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Interest Expenses of $5.5 million for Q1 2026, up 21.72% year-over-year from $4.5 million in Q1 2025, and up 12.16% quarter-over-quarter from $4.9 million in Q4 2025.
Halozyme Therapeutics (HALO) Interest Expenses (2011 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Interest Expenses for 15 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 21.72% year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $19.3 million (up 6.76% YoY), while the FY2025 annual figure was $18.1 million, changed 0.17% from the prior year.
- Interest Expenses advanced to $5.5 million in Q1 2026 per HALO's latest filing, from $4.9 million in the prior quarter.
- Across five years, Interest Expenses topped out at $36.3 million in Q3 2025 and bottomed at -$6.3 million in Q4 2022.
- Historically, Interest Expenses has averaged $5.8 million across 5 years, with a median of $4.5 million in 2024.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 405.11% — and 2025, when it surged 702.67%.
- Halozyme Therapeutics' Interest Expenses stood at -$6.3 million in 2022, then surged by 183.25% to $5.2 million in 2023, then fell by 13.03% to $4.5 million in 2024, then grew by 8.17% to $4.9 million in 2025, then increased by 12.16% to $5.5 million in 2026.
- Business Quant data shows HALO's Interest Expenses at $5.5 million in Q1 2026, $4.9 million in Q4 2025, and $36.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 5.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.90 Mn |
| Jun 30, 2026 | 5.90 Mn |
| Mar 31, 2026 | 5.51 Mn |
| Mar 31, 2026 | 5.51 Mn |
| Dec 31, 2025 | 4.91 Mn |
| Dec 31, 2025 | 4.91 Mn |
| Sep 30, 2025 | 36.31 Mn |
| Sep 30, 2025 | 36.31 Mn |
| Jun 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 4.39 Mn |
| Mar 31, 2025 | 4.53 Mn |
| Mar 31, 2025 | 4.53 Mn |
| Dec 31, 2024 | 4.54 Mn |
| Dec 31, 2024 | 4.54 Mn |
| Sep 30, 2024 | 4.52 Mn |
| Sep 30, 2024 | 4.52 Mn |
| Jun 30, 2024 | 4.52 Mn |
| Jun 30, 2024 | 4.52 Mn |
| Mar 31, 2024 | 4.51 Mn |
| Mar 31, 2024 | 4.51 Mn |